Plasmablastic lymphoma (PBL) can be cured in some patients, but it remains one of the more difficult lymphomas to treat. The estimated 5-year overall survival rate is about 36%, with a median survival of roughly 2.8 years. Those numbers reflect a wide range of outcomes: some patients achieve long-lasting remission, especially with aggressive upfront treatment, while others face early relapse. Your chances depend heavily on the specific biology of the cancer, your overall health, and how well the disease responds to initial therapy.
Why PBL Is Hard to Treat
Plasmablastic lymphoma sits in an unusual space between aggressive lymphoma and plasma cell cancers like myeloma. The cancer cells look and behave like plasma cells (the immune cells that produce antibodies) but grow with the speed of a high-grade lymphoma. This hybrid nature means it doesn’t respond as reliably to standard lymphoma treatments, and it tends to come back after initial therapy. A retrospective analysis of published cases found the relapse or treatment-resistant rate was around 54%.
One important biological factor is what’s happening with the MYC gene in the tumor. When MYC has a specific type of rearrangement called a “split,” patients tend to have significantly worse outcomes compared to those whose MYC gene is normal or only amplified. A multi-center study of 76 patients found that this MYC split roughly doubled the risk of death. If your oncologist orders genetic testing on the tumor, this is one of the key things they’re looking for.
First-Line Treatment: What Works Best
The chemotherapy regimen that has shown the strongest results for PBL is called EPOCH, a combination of five drugs given over several days through continuous infusion. In a study of 93 patients with HIV-related PBL, EPOCH showed clear advantages in complete response rates, progression-free survival, and overall survival compared to the older CHOP regimen. EPOCH is more intensive than CHOP and requires longer infusion times, but the improved outcomes have made it the preferred starting point at most cancer centers.
Adding a drug called bortezomib, which is borrowed from myeloma treatment, appears to boost results further. Bortezomib works by blocking a cellular recycling system that cancer cells rely on to survive. In a study of 16 newly diagnosed PBL patients treated with EPOCH plus bortezomib, 15 out of 16 achieved a complete response. Bortezomib-containing regimens as a whole have shown a 100% overall response rate when used as first-line therapy in one systematic review, though that involved a small group of patients. Even in the relapse setting, bortezomib-based regimens achieved a 90% response rate.
Stem Cell Transplant and Long-Term Remission
For patients who respond well to initial chemotherapy, stem cell transplant using the patient’s own cells offers the best shot at long-term, potentially curative remission. A population-based analysis found that patients who underwent transplant had a median overall survival of about 10.5 years, compared to roughly 3.6 years for those who did not. That’s a striking difference, though only about 1.5% of PBL patients in the study actually received a transplant during their first complete remission. The procedure requires being healthy enough to tolerate intensive chemotherapy beforehand, which limits who qualifies.
The goal of transplant is to wipe out any remaining cancer cells with high-dose chemotherapy and then restore the immune system with previously collected stem cells. Patients who reach complete remission after their initial treatment and then proceed to transplant have the most favorable long-term outlook. For younger, otherwise healthy patients, this is typically the path oncologists recommend.
How HIV Status Affects Outcomes
PBL was originally described in people living with HIV, and it still occurs more frequently in this group. Counterintuitively, HIV-positive patients often do better than HIV-negative patients. One study from Peru found a median overall survival of 43 months in HIV-positive patients compared to just 10 months in HIV-negative patients. The one-year progression-free survival was 74% for HIV-positive patients versus 0% for HIV-negative patients.
Several factors likely explain this. HIV-positive patients tend to be younger at diagnosis, and their cancers may be more driven by the Epstein-Barr virus, which could make them more responsive to chemotherapy. Effective antiretroviral therapy also helps restore immune function, which may contribute to keeping the cancer in check. HIV-negative patients, on the other hand, are often older and may have weaker immune systems due to age or other conditions, making aggressive treatment harder to tolerate.
Options When the Cancer Comes Back
Relapsed PBL is particularly challenging. There is no single established salvage regimen that works reliably, and treatment often involves trying different chemotherapy combinations to find one the cancer responds to. If a response is achieved, proceeding to stem cell transplant offers the best chance of durable remission. In one reported case, a patient with relapsed PBL who did not respond to one salvage regimen responded to a second one and remained in complete remission for over 16 months after transplant.
Newer targeted therapies are expanding the options. Daratumumab, a drug that targets a protein called CD38 found on the surface of PBL cells, has shown activity in relapsed cases. Lenalidomide, an immune-modulating drug also used in myeloma, is another option. These drugs are most often combined with chemotherapy or each other rather than used alone.
CAR-T cell therapy, which engineers a patient’s own immune cells to attack cancer, is being explored for PBL as well. One case report described a patient with PBL that had failed multiple prior treatments who received CAR-T cells targeting two different proteins (CD19 and CD22) and achieved complete remission lasting more than 12 months with no significant side effects. Other case reports have used CAR-T cells targeting a protein called BCMA, with some patients achieving complete remission for six months or longer. These are individual cases rather than large trials, but they suggest CAR-T may become a viable option for patients who have run out of standard treatments.
What Realistic Expectations Look Like
Cure is possible with PBL, but it depends on getting an aggressive, well-chosen treatment upfront and ideally consolidating the response with stem cell transplant. Patients who achieve complete remission after initial therapy have the best prognosis, and achieving that first remission is the single most important milestone. The roughly 36% five-year survival rate reflects the full spectrum of patients, including those who are older, frailer, or unable to tolerate intensive therapy.
For younger patients in good health who respond to EPOCH-based chemotherapy (particularly with bortezomib) and proceed to transplant, the outlook is considerably better than those headline numbers suggest. For older or more fragile patients, the newer targeted drugs offer meaningful responses even when intensive chemotherapy isn’t feasible, though long-term cure rates in this group remain lower.